Literature DB >> 3036943

Identification of interferon-gamma as the lymphokine that mediates leukotriene B4-induced immunoregulation.

M Rola-Pleszczynski, L Bouvrette, D Gingras, M Girard.   

Abstract

Leukotriene B4 (LTB4) has been shown to modulate lymphocyte responses in both a positive and a negative way, depending on the particular cell subsets it interacts with. Recent evidence also indicates that LTB4 can directly affect the production of cytokines such as interleukin 1 (IL 1) or interleukin 2 (IL 2) and interferon-gamma (IFN-gamma). In this report, we present evidence that human T cells pulsed with LTB4 modulate IL 1 production by human monocytes by secreting IFN-gamma. In fact, we found that LTB4-pulsed T cells were capable of inducing a suppression of lymphocyte proliferation if allowed to interact with monocytes, but that this suppression was reversed to an enhancing effect when monocytes were treated with the cyclooxygenase inhibitor indomethacin. Furthermore, LTB4-pulsed T cells released a soluble factor that would mediate both effects. This factor was found to be IFN-gamma, because affinity-purified IFN-gamma could reproduce the effects, and a rabbit polyclonal anti-serum to human IFN-gamma could block the activities of supernatants from LTB4-pulsed T cells. LTB4 was also shown to enhance IFN-gamma production by T4+ T cells and to inhibit IFN-gamma production by T8+ T cells. These results suggest that LTB4 may regulate immune cell functions by inducing IFN-gamma production by T4+ cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036943

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Arachidonic acid metabolism in heat-shock treated human leucocytes.

Authors:  M Köller; W König
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

Review 2.  Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.

Authors:  Sabina Schmitt-Grohé; Stefan Zielen
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

3.  Leukotrienes and macrophage activation: augmented cytotoxic activity and enhanced interleukin 1, tumor necrosis factor and hydrogen peroxide production.

Authors:  L Gagnon; L G Filion; C Dubois; M Rola-Pleszczynski
Journal:  Agents Actions       Date:  1989-01

4.  Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis.

Authors:  R Alten; E Gromnica-Ihle; C Pohl; J Emmerich; J Steffgen; R Roscher; R Sigmund; B Schmolke; G Steinmann
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

5.  Analysis of leukotriene B4 metabolism in human promyelocytic HL-60 cells.

Authors:  S Kasimir; W Schönfeld; R A Hilger; W König
Journal:  Biochem J       Date:  1991-10-01       Impact factor: 3.857

6.  The leukotriene B4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells.

Authors:  C Owman; A Garzino-Demo; F Cocchi; M Popovic; A Sabirsh; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  Leukotriene B4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes.

Authors:  J Stanková; M Rola-Pleszczynski
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

8.  Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses.

Authors:  R S Byrum; J L Goulet; R J Griffiths; B H Koller
Journal:  J Exp Med       Date:  1997-03-17       Impact factor: 14.307

Review 9.  Daily Lifestyle and Inflammatory Skin Diseases.

Authors:  Yu Sawada; Natsuko Saito-Sasaki; Emi Mashima; Motonobu Nakamura
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.